Compare Ascendis Pharma A/S (ASND) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Cognizant Technology Solutions Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Cognizant Technology Solutions Corp trades at $43.15 (market cap $20.13B). The key difference: Ascendis Pharma A/S and Cognizant Technology Solutions Corp are close in size by market cap, and Cognizant Technology Solutions Corp pays a 3.1% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CTSH | |
|---|---|---|
Market Cap | $17.74B | $20.13B |
Sector | Health | Technology |
52-Week High | $277.18 | $86.70 |
52-Week Low | $163.32 | $38.73 |
Enterprise Value | $18.11B | $19.71B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CTSH trades at $42.57, down 1.91% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 9.23 and consistent earnings beats. Recent news highlights AI partnerships with Google Cloud and OpenAI, while cash flow improved in 2025 to $403M. The stock faces near-term pressure from weak demand and competition, but analyst consensus targets $64.33.
The outlook balances attractive valuation against sector rotation headwinds. Opportunities include AI-driven growth and shareholder returns via dividends, but risks involve margin pressure and technical resistance near $44. Wall Street sentiment is mixed with 43% buy ratings, suggesting cautious optimism for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
